Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

Circulation

Volumn 97, Issue 3, 1998, Pages 251-256

  Xiao, Zihui ^a   Théroux, Pierre ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Cell adhesion molecules; Glycoproteins; Heparin; Platelets

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

EID: 0345487533     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.3.251     Document Type: Article

References (36)

1. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
2. Markwardt F, Kaiser B, Novak G. Studies on antithromboric effects of recombinant hirudin. Thromb Res. 1989;54:377-388.
3. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Farreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:64-73.
4. Eika C. Inhibition of thrombin-induced aggregation of human platelets in heparin. Scand J Haematol. 1971;8:216-222.
5. Ellisson N, Edmunds LH, Colman RW. Platelet aggregation following heparin and prournine administradon. Anesthesiology. 1978;48:65-68.
6. Thomson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med. 1973;45:485-494.
7. Eika C. On, the mechanism of platelet aggregation induced by heparin, protamine, and polybrene. Scand J Haematol. 1972;9:248-257.
8. Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol. 1979;9:480-482.
9. Westwick J, Scully MF, Poll C, Kakkar W. Comparison of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res. 1986;42:435-447.
10. Holmer E, Lindhal U, Backstrom G, Thunberg L, Sandberg H, Soderstrom G, Andersson LO. Anticoagulant activities and effects un platelet of a heparin fagment with high affinity for antithrombin. Thromb Res. 1980;18:861-869.
11. O'Brien JR, Shoobridge SM, Finch Wj. Comparison of the effect of heparin and citrate on platelet aggregation. J Clin Pathol. 1969;2:28-30.
12. Besterman EMM, Gillett MPT Heparin effects on plasma lecithin formation and platelet aggregation. Atherosclerosis. 1973;17:503-513.
13. Heiden D, Mielke CH Jr, Rodvien R. Impairment by heparin of primary haemostasis and platelet (14C)5-hydroxytryptamine release. Br J Haematol. 1977;36:427-436.
14. Fernandez F, N'Guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res. 1986;43:491-495.
15. Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Sem Hematol. 1980;17:259-291.
16. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent antibodies and flow cytometry. Blood. 1987;70:307-315.
17. Warkentin TE, Powling MJ, Hardisty RM. Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. Br J Haematol. 1990;76:387-394.
18. Hsu-Lin SC, Berman CL, Furie BC, August D, Furie B. A platelet membrane glycoprotein expressed during platelet activation. J Biol Chem. 1984;259:9121-9126.
19. McEver RP, Martin MN. A monoclonal antibody to a membrane glyco-protein binds only to activated platelet. J Biol Chem. 1984;259:9799-9804.
20. Jackson CW, Jennings LK. Heterogeneity of fibrinogen receptor expression on platelets activated in normal plasma with ADP: analysis by flow cytometry. Br J Haematol. 1989;72:407-414.
21. Hjemdahl P, Chronos NA, Wilson DJ, Bouloux P, Goodal AH. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb. 1994;14:77-84.
22. Goldstad G, Solumn N, Krutnes MB. Heparin binding platelet proteins demonstrated by crossed affinity immunoelectrophoresis. Br J Haematol. 1983;53:563-566.
23. Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res. 1988;50:815-826.
24. Horne MK. Heparin binding to normal and abnormal platelets. Thromb Res. 1988;51:135-144.
25. 2. Science. 1979;205:499-501.
26. Coughlin SR, Vu TKH, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest. 1992; 89:351-355.
27. Weitz J, Huboda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antitbrombin but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest. 1990;86:385-391.
28. Carter CJ, Kelton JG, Hirsh J, Gent M. Relationship between the antithrombotic and the anticoagulant effects of low molecular weight heparin. Thromb Res. 1981;21:169-174.
29. Cade JF, Buchanan MR, Boeu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and hemorraghic effects of low molecular weight heparin fractions. Thromb Res. 1984;35:613-625.
30. Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation. 1989;80:1617-1626.
31. Théroux P, Waters D, Lam J, Juneau M, McCans, J. Reactivation of unstable angina after the discontinuation of heparin. N Eng J Med. 1992; 327:141-145.
32. Melina G, Colivicchi F, Bevilacqua E, Mangnanimi S, Melina D. Blood pressure variations, hemorheological determinants, and platelet aggregation in hypertensive patients with unstable angina. Clin Exp Hypertens. 1995; 17:1145-1156.
33. al-Nozha M, Gader AM, al-Momen AK, Noah MS, Jawaid M, Arafa M. Haemostatic variables in patients with unstable angina. Int J Cardiol. 1994; 43:269-277.
34. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
35. Théroux P, Latour JG, Leger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation. 1987;75:156-162.
36. Tofler GH, Berzinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.